Upward trend in infections continues Infections with the coronavirus SARS-CoV-2 in the Netherlands have increased for the third week in a row. The number of patients admitted to hospital nursing wards remained the same this week.
6 people in the Netherlands with monkeypox There are now 6 cases of monkeypox in humans in the Netherlands. Science Photo Library / ANP
First patient with monkeypox in the Netherlands This afternoon, a patient with monkeypox was confirmed in the Netherlands for the first time. RIVM researchers confirmed that the person has monkeypox with a PCR test. Science Photo Library / ANP
Even after COVID-19 crisis, social isolation continues Even after most coronavirus measures have been discontinued, some people are still living in social isolation to avoid COVID-19 exposure.
Number of tuberculosis patients in the Netherlands increased slightly in 2021 compared to 2020 The number of people with tuberculosis (TB) in the Netherlands increased slightly in 2021, reaching 680. This figure is 9% higher than it was in 2020 (622 patients).
Decrease in SARS-CoV-2 hospital admissions, fewer people tested 1,214 patients with a SARS-CoV-2 infection were admitted to hospital in the Netherlands in the past week*, a decrease of 12% compared to the week before that.
Impact of coronavirus outbreak on participation in National Immunisation Programme limited Participation in the vaccinations against mumps, measles and rubella (MMR) and diphtheria, pertussis (whooping cough), tetanus and polio) (DTaP-IPV) has decreased slightly among infants (-1%).
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
RIVM to play greater role in tuberculosis control The Committee for Practical Tuberculosis Control (CPT) will be transferred per 1 January 2022 to the National Institute for Public Health and the Environment (RIVM) after a period of 70 years with KNCV Tuberculosis Foundation.
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).